PMID- 2735662
OWN - NLM
STAT- MEDLINE
DCOM- 19890714
LR  - 20190616
IS  - 0077-8923 (Print)
IS  - 0077-8923 (Linking)
VI  - 556
DP  - 1989
TI  - Relative efficacy of heparin and related glycosaminoglycans as antithrombotic 
      drugs.
PG  - 313-22
AB  - In a standardized animal model, unfractionated heparin (UFH) prevents venous 
      thrombogenesis at a dose of 80 micrograms/kg. Oligosaccharide fragments of 
      heparin, with very high anti-Xa activity both in vitro and in ex vivo plasma 
      samples were less effective than UFH in preventing thrombosis. A decasaccharide 
      fragment was virtually inactive in impairing thrombosis at this dose, although a 
      20-22 monosaccharide fragment showed some impairment. Dermatan sulfate, which has 
      no anti-factor Xa activity, partially impairs both thrombin generation and stasis 
      thrombosis. However, dermatan sulfate could not suppress thrombin generation 
      below about 35% of control at the doses studied. Neither oligosaccharides nor 
      dermatan sulfate were as effective on a weight basis as UFH in impairing 
      thrombosis, particularly after 20 minutes' stasus. Maximal antithrombotic effects 
      are achieved when both factor Xa and thrombin are inhibited. Drugs which act 
      primarily on factor Xa (oligosaccharides) or thrombin by non-ATIII pathways 
      (dermatan sulfate) are less efficient than UFH as antithrombotic drugs.
FAU - Thomas, D P
AU  - Thomas DP
AD  - Department of Haematology, National Institute for Biological Standards and 
      Control, Potters Bar, Hertfordshire, United Kingdom.
FAU - Merton, R E
AU  - Merton RE
FAU - Barrowcliffe, T W
AU  - Barrowcliffe TW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Oligosaccharides)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 24967-94-0 (Dermatan Sulfate)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Animals
MH  - Dermatan Sulfate/therapeutic use
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Factor Xa
MH  - Glycosaminoglycans/administration & dosage/*therapeutic use
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Oligosaccharides/therapeutic use
MH  - Partial Thromboplastin Time
MH  - Rabbits
MH  - Serine Proteinase Inhibitors
MH  - Thrombin/metabolism
MH  - Thrombophlebitis/blood/*drug therapy
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1111/j.1749-6632.1989.tb22513.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 1989;556:313-22. doi: 10.1111/j.1749-6632.1989.tb22513.x.